Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.45 |
| ▸ | HPN | P05981 | 3/20 | 0.45 |
| ▸ | HGFAC | Q04756 | 3/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860211 | 1.00 | PRSS1 (0.45) | PRSS1TPSAB1HPNHGFACST14 | |
| SCHEMBL5860218 | 1.00 | PRSS1 (0.45) | PRSS1TPSAB1HPNHGFACST14 | |
| SCHEMBL5861617 | 0.87 | F2 (0.46) | F2 | |
| SCHEMBL5860229 | 0.87 | PRSS1 (0.44) | PRSS1TPSAB1F2 | |
| SCHEMBL5860224 | 0.87 | PRSS1 (0.44) | PRSS1TPSAB1F2 | |
| SCHEMBL5861388 | 0.85 | PRSS1 (0.46) | PRSS1TPSAB1 | |
| SCHEMBL18866505 | 0.84 | F2 (0.47) | F2 | |
| SCHEMBL18866677 | 0.84 | F2 (0.47) | F2 | |
| SCHEMBL14127426 | 0.84 | PRSS1 (0.48) | PRSS1TPSAB1 | |
| SCHEMBL5860154 | 0.82 | F2 (0.60) | PRSS1TPSAB1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | COSTANZO MICHAEL J (US) | 2003-01-09 | — | — | US | claimed |
| US-7132418-B2 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | COSTANZO MICHAEL J (US) | 2003-01-09 | — | — | US | disclosed |
| US-6469036-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES ASSOCIATED WITH THE RESPIRATORY TRACT, SUCH AS ASTHMA AND ALLERGIC RHINITIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008829-A1 | Peptidyl heterocyclic ketones useful as tryptase inhibitors | CMA1, TPSB2, TPSAB1 | PRSS1 9/4885TPSAB1 3/4885HPN 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.